DeSci Boom Or Bust?
At the beginning of 2025, the Decentralized Science (DeSci) movement experienced significant momentum, marked by several key developments such as the emergence of new projects, market growth and investment, technological advancements, and community and collaboration. However, recent developments in the industry have presented substantial market challenges for DeSci tokens.
According to Binance, one of DesSci's most prolific tokens took a large plummet. BIO Protocol (BIO) after a meteoric rise of 2,700%, BIO's value plummeted to $0.1214 by March 7, 2025, erasing approximately $1.1 billion in market capitalization. This decline was attributed to market saturation, profit-taking, geopolitical tensions, and stalled adoption within the biotech community.
Disrupting Traditional Science or Just Another Crypto Hype? – Nansen Insights
Nansen Insights, newly released report: DeSci – The Future of Science or Pure Window Dressing? penned by Research Analyst - Nicolai Sondergaard, examines whether DeSci is genuinely solving issues within the scientific community or if it's part of a broader trend within the evolving crypto landscape. The report asserts the world of decentralized science (DeSci) has been volatile, with tokens linked to DeSci projects seeing explosive early gains of up to 1,000% before crashing by as much as 74%. Despite these dramatic fluctuations, interest in DeSci continues to grow, driven by the promise of transforming scientific research and funding. Nansen's latest report,
Nicolai's Key Takeaways Regarding DeSci Reflected in the Report Are:
While the DeSci movement aims to revolutionize scientific research through decentralization and blockchain technology, its associated tokens currently face significant market challenges. The future trajectory will depend on addressing adoption barriers, clarifying regulatory frameworks, and demonstrating tangible benefits to the scientific community.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows: 7:00 am ET, on-demand corporate presentation 11:00 am ET, 'Pivotal-Stage Assets for Retinal Disorders' panel discussion Webcast Link InstructionsA webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: The replays will be archived for 90 days following the presentation date. About Belite BioBelite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Media and Investor Relations Contact:Jennifer Wu ir@ Julie Fallonbelite@
Associated Press
3 days ago
- Associated Press
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2025, and provided a general business update. 'This quarter, we remained on track with the strategic objectives we outlined at the start of the year, including the completion of enrollment in our pivotal Phase 3 PHOENIX trial — an important milestone in our development efforts for people living with geographic atrophy,' said Dr. Tom Lin, Chairman and CEO of Belite Bio. 'We also received Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease from the FDA, underscoring its potential as the first-ever treatment for this patient population and acknowledging the significant unmet need for people living with this debilitating disease. With the DRAGON trial on track to complete by the end of this year, we remain focused on advancing Tinlarebant toward key clinical and regulatory milestones.' Second Quarter 2025 Business Highlights and Upcoming Milestones: Clinical Highlights Tinlarebant (LBS-008) is an oral, potent, once-daily, retinol binding protein 4 (RBP4) antagonist that decreases RBP4 levels in the blood and reduces vitamin A (retinol) delivery to the eye without disrupting systemic retinol delivery to other tissues. Vitamin A is critical for normal vision but can accumulate as toxic byproducts in individuals affected with STGD1 and GA, the advanced form of dry age-related macular degeneration (AMD), leading to retinal cell death and loss of vision. Corporate Highlights Second Quarter 2025 Financial Results: Current Assets: As of June 30, 2025, the Company had $149.2 million in cash, liquidity funds, time deposits, and U.S treasury bills. R&D Expenses: For the three months ended June 30, 2025, research and development expenses were $11.0 million compared to $9.1 million for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $20.4 million compared to $15.8 million for the same period in 2024. The increase in research and development expenses in both the quarter and year-to-date was primarily attributable to (i) higher pass-through expenses related to the PHOENIX trial and manufacturing expenses payments, partially offset by lower DRAGON trial expenses and a development milestone payment for the completion of a phase 2 trial in 2024; (ii) an increase in share-based compensation expenses. G&A Expenses: For the three months ended June 30, 2025, general and administrative expenses were $6.5 million compared to $1.4 million for the same period in 2024. For the six months ended June 30, 2025, general and administration expenses were $12.7 million compared to $3.0 million for the same period in 2024. The increase in general and administrative expenses in both the quarter and year-to-date was primarily due to an increase in share-based compensation expenses. Other Income: For the three months ended June 30, 2025, other income was $1.3 million compared to $1.0 million for the same period in 2024. For the six months ended June 30, 2025, other income was $2.5 million compared to $1.4 million for the same period in 2024. The increase in both the quarter and year-to-date was attributed to interest from time deposits and U.S. treasury bills. Net Loss: For the three months ended June 30, 2025, the Company reported a net loss of $16.3 million, compared to a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, the Company reported a net loss of $30.6 million, compared to a net loss of $17.4 million for the same period in 2024. Webcast Information Belite Bio will host a webcast on Monday, August 11, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update. To join the webcast, please visit A replay will be available for approximately 90 days following the event. About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words 'expect', 'hope' and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio's drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the 'Risk Factors' section in Belite Bio's filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Media and Investor Relations Contact: Jennifer Wu [email protected] Julie Fallon [email protected]
Yahoo
06-08-2025
- Yahoo
Bio-Techne (NASDAQ:TECH) Exceeds Q2 Expectations
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 3.5% year on year to $317 million. Its non-GAAP profit of $0.53 per share was 6.1% above analysts' consensus estimates. Is now the time to buy Bio-Techne? Find out in our full research report. Bio-Techne (TECH) Q2 CY2025 Highlights: Revenue: $317 million vs analyst estimates of $314.7 million (3.5% year-on-year growth, 0.7% beat) Adjusted EPS: $0.53 vs analyst estimates of $0.50 (6.1% beat) Adjusted EBITDA: $115.6 million vs analyst estimates of $110.2 million (36.5% margin, 4.9% beat) Operating Margin: -7.5%, down from 15% in the same quarter last year Free Cash Flow Margin: 29.4%, up from 18.8% in the same quarter last year Organic Revenue rose 3% year on year (0.7% in the same quarter last year) Market Capitalization: $8.57 billion "Bio-Techne delivered a solid fourth quarter that was in-line with our expectations, despite ongoing market uncertainty," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. Company Overview With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Thankfully, Bio-Techne's 10.5% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Bio-Techne's recent performance shows its demand has slowed as its annualized revenue growth of 3.6% over the last two years was below its five-year trend. Bio-Techne also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Bio-Techne's organic revenue averaged 3.1% year-on-year growth. Because this number aligns with its two-year revenue growth, we can see the company's core operations (not acquisitions and divestitures) drove most of its results. This quarter, Bio-Techne reported modest year-on-year revenue growth of 3.5% but beat Wall Street's estimates by 0.7%. Looking ahead, sell-side analysts expect revenue to grow 5.1% over the next 12 months, an improvement versus the last two years. This projection is above the sector average and suggests its newer products and services will spur better top-line performance. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin Bio-Techne has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 20.6%. Analyzing the trend in its profitability, Bio-Techne's operating margin decreased by 17.1 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 17.9 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. This quarter, Bio-Techne generated an operating margin profit margin of negative 7.5%, down 22.5 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Bio-Techne's remarkable 11.2% annual EPS growth over the last five years aligns with its revenue performance. This tells us it maintained its per-share profitability as it expanded. In Q2, Bio-Techne reported adjusted EPS at $0.53, up from $0.49 in the same quarter last year. This print beat analysts' estimates by 6.1%. Over the next 12 months, Wall Street expects Bio-Techne's full-year EPS of $1.93 to grow 7.1%. Key Takeaways from Bio-Techne's Q2 Results It was good to see Bio-Techne narrowly top analysts' organic revenue expectations this quarter. We were also happy its EPS outperformed Wall Street's estimates. Overall, this print had some key positives. Investors were likely hoping for more, and shares traded down 2.2% to $53.40 immediately after reporting. Is Bio-Techne an attractive investment opportunity right now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
